Icon Plc $ICLR Shares Sold by Brant Point Investment Management LLC

Brant Point Investment Management LLC cut its holdings in shares of Icon Plc (NASDAQ:ICLR) by 40.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,000 shares of the medical research company’s stock after selling 4,000 shares during the quarter. Brant Point Investment Management LLC’s holdings in Icon were worth $1,093,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Sanctuary Advisors LLC lifted its holdings in Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after buying an additional 56 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after buying an additional 56 shares in the last quarter. New Wave Wealth Advisors LLC lifted its holdings in Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after buying an additional 72 shares in the last quarter. Signaturefd LLC lifted its holdings in Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after buying an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after buying an additional 93 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on ICLR. Jefferies Financial Group reiterated a “buy” rating and set a $165.00 target price on shares of Icon in a report on Friday, May 29th. Citigroup increased their target price on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. JPMorgan Chase & Co. increased their target price on shares of Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Finally, Leerink Partners set a $145.00 target price on shares of Icon in a report on Thursday, May 28th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Icon presently has an average rating of “Hold” and a consensus target price of $156.44.

Icon Price Performance

Shares of ICLR opened at $146.18 on Friday. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The firm’s fifty day simple moving average is $121.76 and its 200-day simple moving average is $140.47. The firm has a market capitalization of $11.19 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 11.55 and a beta of 1.26. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same period last year, the business earned $3.43 EPS. The company’s revenue was up 2.5% on a year-over-year basis. Equities analysts forecast that Icon Plc will post 9.74 EPS for the current fiscal year.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.